Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation

Authors: Peng Chen, Xuejie Li, Ruonan Zhang, Shuiping Liu, Xiang Yu, Mingming Zhang, Xiaying Chen, Ting Pan, Lili Yan, Jiao Feng, Ting Duan, Da Wang, Bi Chen, Ting Jin, Wengang Wang, Liuxi Chen, Xingxing Huang, Wenzheng Zhang, Yitian Sun, Guohua Li, Lingpan Kong, Xiaohui Chen, Yongqiang Li, Zuyi Yang, Qin Zhang, Lvjia Zhuo, Xinbing Sui, Tian Xie - Theranostics 2020 cited by 388

: Our data for the first time suggest that the natural product β-elemene is a new ferroptosis inducer and combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant CRC cells by inducing ferroptosis and inhibiting EMT, which will hopefully provide a prospective strategy for CRC patients with RAS mutations.